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Oral immunoglobulin (Ig) preparations are prime examples of medicinal nutrition from natural sources. Plasma
products containing Ig have been used for decades in animal feed for intestinal disorders to mitigate the damaging
effects of early weaning. These preparations reduce overall mortality and increase feed utilization in various animal
species leading to improved growth. Oral administration of Ig preparations from human serum as well as bovine
colostrum and serum have been tested and proven to be safe as well as effective in human clinical trials for a
variety of enteric microbial infections and other conditions which cause diarrhea. In infants, children, and adults, the
amount of intact IgG recovered in stool ranges from trace amounts up to 25% of the original amount ingested. It is
generally understood that IgG can only bind to antigens within the GI tract if the Fab structure is intact and has
not been completely denatured through acidic pH or digestive proteolytic enzymes. This is a comprehensive review
of human studies regarding the survivability of orally-administered Ig preparations, with a focus on IgG. This review
also highlights various biochemical studies on IgG which potentially explain which structural elements are responsible
for increased stability against digestion.
Keywords: Serum-derived bovine immunoglobulin, Bovine colostrum, Serum-derived human immunoglobulin,
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The biological role of immunoglobulins (Ig) in the
protection of the gastrointestinal (GI) tract is well-
established, particularly the role of Ig in colostrum and
breast milk [1,2]. Hence, colostrum and breast milk are
categorized as medicinal nutrition. Due to the need for
pasteurization, however, Ig preparations from these
sources will have inconsistent amounts of IgG since
the amount of IgG denaturation depends upon both
the quality of the colostrum and exact method of
pasteurization [3]. Efficacy of these formulations in vari-
ous enteropathies in humans also depends upon the Ig
surviving past the stomach into the small and large
bowels.
It is generally well-recognized that secretory IgA
(sIgA), the primary class of Ig in human colostrum and* Correspondence: victoria.jasion@enterahealth.com
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unless otherwise stated.breast milk as well as being found in the intestinal tract,
are stable against enzymatic degradation. Other Igs, such
as IgG and IgM, are also less susceptible than typical
dietary proteins to digestion, yet this knowledge remains
underappreciated despite numerous clinical studies in
humans which illustrate recovery of intact and immuno-
logically active IgG from the ileum and feces [4-7]. The
purpose of this review is to summarize human clinical
studies which assess digestibility of IgG purified from ei-
ther colostrum or serum in ileal aspirates and stool. This
review also summarizes in vitro biochemical studies that
have assessed structural features of IgG which contribute
to their overall stability and discusses for the first time
the proposed structural basis for resistance to digestion
in the GI tract. With the introduction to the market of
the first nutritional therapy in the form of a physician
supervised medical food containing high levels of IgG
from bovine sera, it is important to understand the
pharmacokinetics of these molecules. This understanding is
necessary for the usefulness of any Ig-containing formulationentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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orders [8].
Review
Immunoglobulin survival through the gastrointestinal
tract: clinical data
Numerous studies have been performed demonstrating
that Ig preparations derived from human sera as well as
bovine colostrum and sera survive past the stomach,
throughout the GI tract, and are present in fecal matter.
These studies are summarized in Table 1. IgG was the
predominant Ig in these preparations, but often either
IgA and/or IgM was present in smaller amounts.
Recovery in infants
Many of the first published clinical studies on the digest-
ibility of orally-administered IgG were conducted in in-
fant populations. Zinkernagel et al. [9] fed 10 healthy
infants at less than three weeks of age a lyophilized
bovine colostrum preparation containing 70% IgG ad-
ministered at 2 g/kg/d. An average 13%-20% of the Ig
survived undigested in the stool as demonstrated by
an agglutination assay against E. coli antigens [9]. In
addition, recovered titer correlated with the amount of
undigested IgG. In another study, 6 healthy immature,
formula-fed infants ingested a 10% human immune
serum globulin (HISG), predominantly IgG, in divided
doses of 1 to 8 ml/kg/day over 5 consecutive days [10].
The survival of IgG in stool over a 24 hour period
ranged between 4-12% of the original IgG ingested. Vari-
ability per subject was observed in the survival of active
IgG in feces; however, increasing doses were associated
with higher amounts of IgG excreted per day. There was
no evidence of systemic absorption or adverse events.
In a larger randomized, controlled clinical trial, low-
birth weight infants unable to breast feed were adminis-
tered 600 mg daily of serum-derived human IgA (73%)
and IgG (26%). The test group (n = 91) ingested the
serum-derived IgA-IgG mixed into either infant formula
or infant formula combined with pooled, pasteurized
human milk. The control group (n = 88) ingested the
same formula/milk preparation, less the serum-derived
IgA-IgG [11]. The infants receiving oral IgA-IgG had
fewer cases of necrotizing colitis (0 cases) compared to
the controls (6 cases) and had “substantial amounts” of
intact IgA and IgG recovered in stool compared to the
controls. As in the previous study, there was no evidence
of systemic absorption.
Bovine milk Ig concentrate purified from hyper-
immunized cows against four human rotavirus serotypes
has also been studied in a group (n = 164) of low birth
weight infants [12]. The infants were dosed at 2 g Ig
concentrate/kg/day for five days. Of the infants receiving
Ig, stool samples from 47% had detectable bovine IgGand 43% maintained rotavirus-neutralization activity
against bovine rotavirus V1005, human rotavirus Wa
(serotype 1) and simian rotavirus SA-11 in cell culture.
Furthermore, the infants with high amounts of neutraliz-
ing activity still present in feces demonstrated clinical
benefit [12].
Recovery in children
One small (N = 3) and another larger study (N = 105)
have been performed to assess recovery of active IgG
against rotavirus from feces of children [13,14]. The
smaller study was comprised of three pediatric patients
ages 16 months and 4 yr, both with severe combined
immunodeficiency disease, and 18-yr-old with common
variable immunodeficiency disease [13]. All three had a
history of intermittent positive excretion of rotavirus
serotype 1 with chronic diarrhea, decreased weight gain
and fat malabsorption. The children ingested a single
dose of 150 mg/kg human sera Ig (IgG at 50 mg/ml)
labeled with 125I. Approximately 50% of the recovered
radioactivity was excreted in the stools over a 3 d period.
Half of the excreted radioactively labeled IgG, or 25% of
the originally ingested IgG, retained immunological ac-
tivity, as determined by the recovery of 125I-labeled Ig
bound to rotavirus [13].
In the second study, children drank 100 ml of whole
cow’s milk supplemented with hyperimmunized bovine
colostrum against rotavirus, 3 times daily for a period of
6 days [14]. There were five groups based on the
rotavirus-antibody titer of the Ig formulation: control
(no rotavirus antibody titer), 1:2,500, 1:5,100, 1:8,000,
and 1:8,200. After pooling results from the four experi-
mental groups, approximately 5% of IgG was recovered
while the level of antibody activity varied considerably.
Approximately 88% of the experimental patients had de-
tectable neutralization signals which correlated (r = 0.81)
with percent reduction of rotavirus from stools and the
titer of ingested milk/colostrum.
Recovery in adults
Two studies in adults measured the ileal recovery of
orally-administered Igs [4,6]. Healthy, fasted subjects
(n = 7) drank 400 ml of a 15N-labeled bovine colostrum-
derived Ig fraction, containing approximately ~5.2% IgG,
0.86% IgM, and 0.1% IgA (~2 g IgG, 0.34 g IgM, and
0.04 g IgA) and ileal effluents were collected every
20 min for 8 hrs [4]. Approximately 19% of IgG and IgM
was still immunologically active from ileal effluent,
although the titer was not reported. The authors also
reported that 59% of IgG collected from 2 subjects
in the jejunum remained active. Further purification
of the ileal chyme samples using protein chromatography
demonstrated that the fractions with the most immuno-
logical activity had a molecular weight of ~100 kDa
Table 1 Clinical studies assessing survival of orally-administered immunoglobulin preparations through the digestive tract in humans
Population (n), health status Donor species Preparation Amount of Ig
ingested daily
Material* Recovery Recovered immunological
activity
Reference
Infant (10), healthy Bovine Powder 2 g/kg IgG (70%), C 13% Yes (titer correlated with
% IgG recovered)
Zinkernagel, et al. (1972) [9]
Infant (6), healthy Human Liquid 1 – 8 ml/kg
(152 – 1120 mg of IgG)
IgG (~99%), S 4-12% Yes (titer, 1:2) Blum, et al. (1981) [10]




NR Eibl et al. (1988) [11]
Infant (164), rotaviral
gastroenteritis




Human Liquid 150 mg/kg IgG (% NR), S ~25% Yes (titer NR, recovery
as intact immune
complex, Ig + rotavirus)
Losonsky, et al. (1985) [13]
Children (105), healthy Bovine (hyperimmunized) Liquid (one
Powder Group)
NR as gram of Ig Ig (% NR), C 5% Yes (titer correlated with
initial dose)
Pacyna, et al. (2001) [14]
Adult (65), cholera Bovine (hyperimmunized) Powder 4 g Ig or 16 g Ig IgG (~94%), C 10-20% Yes (titer NR) McClead, et al. (1988) [17]
Adult (7), healthy Bovine Powder 24.4 g Ig IgG (84%) – IgM
(14%), C
~19%† Yes (titer NR) Roos, et al. (1995) [4]
Adult (6), healthy Bovine (hyperimmunized) Powder 2.1 g IgG IgG (% NR), C 49%† Yes (titer correlated with
% IgG recovered)
Warny, et al. (1999) [6]
Adult (6), healthy Bovine (hyperimmunized) Powder 14.2 g IgG or 3.4 g IgG IgG (% NR), C 1.6-32.7% Yes (titer NR) Kelly, et al. (1997) [5]
Adult (50), healthy & challenged
with S. flexneri
Bovine (hyperimmunized) Liquid NR as gram of Ig IgG (% NR), C ǂ Yes (titer, ≥ 1:8) Tacket, et al. (1992) [16]
Adult (72), bone marrow
transplant patients
Human Liquid 50 mg/kg body weight IgG (% NR), S 1-80 mg/dL
of feces
NR Copelan, et al. (1994) [18]
Adult (12), healthy Bovine Powder NR as gram of Ig IgG (% NR), S ǂ NR Hanning, et al. (1994) –
Unpublished, Data on File.
Adult (4), healthy Bovine Powder 0.5 g, 2.5 g or 10 g IgG IgG (% NR), C <0.01% NR Bogstedt, et al. (1997) [19]
Adult (8), healthy Bovine Liquid 7.65 g IgG IgG, C <0.1% No Lissner, et al. (1998) [20]
†Amount collected from the ileum.
ǂ Indicates the presence of immunoglobulin in stool.
*S = serum; C = colostrum; M =milk concentrate.
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trypsin digestion experiments of the intact IgG (~160 kDa)
into Fab1,2 dimers (~100 kDa) and monomers (~50 kDa)
[15]. Thus, in addition to demonstrating IgG survivability
through the gastric environment into the ileum, these data
establish that in vivo IgGs are digested in a step-wise man-
ner into active, intact Fab fragment that still bind target
antigen (s).
In the second ileal recovery study, 6 healthy volunteers
with an end ileostomy ingested 5 g of bovine-Ig concen-
trate from hyperimmune bovine colostrum against
C. difficile which contained 2.1 g of IgG alone, with an
antacid, during treatment with omeprazole (a proton-
pump inhibitor which decreases the acidity of the stom-
ach), or within enteric-coated capsules in four separate
experiments [6]. The difference in IgG recovered was
not statistically significant: alone (49%), antacid (30%)
and omeprazole (50%) (p = 0.13). Counterintuitively,
enteric encapsulation resulted in statistically less IgG
reaching the ileum (4%) during the time course, com-
pared with both the alone and omeprazole group. Some
capsules were recovered intact or partially digested, sug-
gesting that enteric encapsulation inhibited release of
IgG in the small intestine. Percent recovery of IgG cor-
related with neutralizing activity of toxin A. These two
studies illustrate that a high percentage of orally-
administered IgG (between ~19% and ~50%) can be re-
covered intact and active from the distal ileum in adult
humans before entering the large intestine.
Fecal recovery of orally-administered Igs has also been
demonstrated in healthy adults. In one study, healthy
adult volunteers (n = 6) took a single oral dose of bovine
Ig concentrate (BIC, 45 g with 14.2 g of IgG) from the
colostrum of hyperimmunized cows against C. difficile
[5]. Each subject had a 14-day wash-out period between
crossing-over into one of six testing groups: fasting (45 g
BIC), fed (45 g BIC), fed (8 g BIC), co-administered with
antacid (45 g BIC), with omeprazole (45 g BIC), and
enteric-coated capsules (8 g BIC) designed to release the
product at pH > 6 in the intestinal tract. Total bovine
IgG and specific anti-C. difficile IgG activity were mea-
sured in feces. The bovine IgG concentration of the fast-
ing group compared to the ingested dose of 45 g BIC
after 72 hr in feces was 3.8%, for fed 1.6%, and for ant-
acid 2.7%. Omeprazole increased fecal bovine IgG levels
to 8.8%, although not statistically significant over the
other groups. In this study, the stool samples from
enteric-coated capsules had 32.7% of the IgG in the ori-
ginal dose, 8 g BIC. For the fed group ingesting 8 g BIC,
the recovery was 0.6% the original dose. C. difficile neu-
tralizing activity correlated with the percentage of IgG
recovered. This study showed that enteric encapsulation
of oral Ig correlated with higher amounts of IgG recov-
ered in stool and therefore delivered more intact IgG tothe colon in healthy adults. Further studies are required
to determine whether enteric encapsulation is necessary
to protect orally delivered Ig for efficacy in specific in-
testinal disorders.
Tacket et al. [16] administered two specific prepara-
tions of bovine colostrum against Shigella flexneri 2a
strain 5427 T liposaccharide, anti-LPS IgG which varied
by titer of anti-LPS (1:2,560 and 1:40,960, respectively)
and addition of chocolate dairy protein powder (1:40,960
titer only) to healthy adults (n = 50). The healthy adults
were challenged with 103 c.f.u. of S. flexneri 2a strain
2457 T after three days of ingesting the Ig concentrates
above. Bovine IgG was detected in feces at 91% (1:2,560)
and 60% (1:40,960) of the original amounts. In both
groups, the recovered titer of bovine anti-LPS was ≥ 1:8.
This study illustrated a dose–response effect since the
group with the higher titer was better protected from
S. flexneri challenge. In another report of two trials, 2 g
of bovine Ig concentrate from the colostrum of cows
hyperimmunized against cholera toxin was administered
to patients with active cholera diarrhea under different
protocols: two doses (4 g bovine Ig concentrate, n = 45)
or a single dose for every two hours for a total of eight
doses (16 g of Ig concentrate, n = 20). From the 65 pa-
tients, a total of 35 individual stool samples were ana-
lyzed for bovine IgG and IgA. Low levels of active Ig,
either as whole IgG or Fab fragments, was found in stool
for roughly 60% of the patients ingesting bovine Ig. An
average of about 10-20% cholera toxin neutralizing activ-
ity was still present in the recovered stools, although the
titer was not reported [17]. In another randomized,
controlled trial, patients undergoing bone marrow trans-
plantation (N = 72) who received either 50 mg/kg human
gammaglobulin or placebo daily in four divided doses
for 28 days after the procedure (500 mg weekly), there
was 1 to 80 mg/dL of IgG present in stool. Antibody
reactivity was not reported [18].
Other trials reporting only trace amounts of IgG in
feces have also been performed. In an unpublished study
of 12 healthy adults, when 10 g of serum-derived bovine
immunoglobulin/protein isolate (SBI) was given on two
consecutive days followed by 2.5 g for 14 days, there
were only low levels of detectable IgG in feces [Hanning,
R. and M. Drew, Bovine Immunoglobulin Feeding Trial.
Data on File, 1994]. There was no detectable bovine Ig
in the serum of any subjects again supporting the notion
of no intact systemic circulation of bovine-derived Ig. In
another study, when 0.5, 2.5, or 10 g of bovine IgG was
administered to 4 healthy adults, only 0.01% of the
ingested IgG was detected in feces. Neutralizing activity
of this recovered fraction was not assessed [19]. Simi-
larly, when a 15 g colostrum preparation from non-
immunized cows with an IgG concentration of 51%
was given to healthy volunteers (n = 8), there was no
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urine) and in 3 of the 8 patients there were only trace
amounts of bovine IgG detected in feces, but without
antibody reactivity to Yersinia enterocolitica and Cam-
pylobacter jejuni antigens [20]. These data suggest that
the study population may be an important determinant
in recovery Ig and neutralizing activity. In healthy indi-
viduals with normal transit times, there appears to be
less recovery of orally administered Ig compared to pa-
tients with accelerated intestinal transit due to infection
or disease.
Recovered IgG values varied from study to study. This
is not surprising since each study had different patient
populations and various immunoglobulin preparations.
Yet, these data summarized above strongly suggest that
IgG are more resistant to complete digestion throughout
the human GI tract than other dietary proteins since
only three of the fifteen reports illustrate trace amounts
of IgG recovered. It should be mentioned that with re-
spect to nutrition literature, the term “digestibility” is
most recently defined as the net absorption of an
amino acid [21]. In this review, we are using the term
“digestibility” to discuss the integrity of the quaternary
and tertiary structure of IgG as it passes through the GI
tract in humans, as it is generally understood that IgG
can only bind to antigens within the GI tract if the anti-
gen binding domain, the Fab, is intact. This would mean
the Fab domain must resist complete denaturation
through acidic pH and complete digestion by proteolytic
enzymes. Most of the human studies summarized above
for IgG assessed crude protein digestibility because they
reported a percentage of intact IgG recovered, either
from the ileum or from feces. As aforementioned, the
many nutrition experiments which assess the digestibility
of other dietary proteins are reported as percentages as a
function of the net absorption of an amino acid. There-
fore, it is difficult to compare the digestibility of IgG as
reported in this review (crude protein) to the digestibility
of other dietary proteins reported in literature (ileal di-
gestibility as absorbed amino acids). In order to provide
some sort of comparable measure, the true ileal digest-
ibility - as defined as absorbed amino acids - of other
dietary proteins in humans are: 95% for milk proteins,
94.1% for casein, 90% for pea protein, 91.5% for wheat
protein [22]. There is one study reviewed in this manu-
script which could conservatively be compared to the
above numbers. Roos et al. [4], reported a prececal nitro-
gen absorption from the Ig preparation to be at 79%,
below the absorption percentages mentioned above for
other dietary proteins. In addition, recovered active frag-
ments corresponding to ~100 kDa or two Fab domains
were purified from the recovered chyme. This study
therefore directly corroborates the step-wise process by
which IgG are digested by enzymes in vitro also occurs inhumans in vivo and that Ig preparations are digested
more slowly, corresponding to less amino acid absorption
via nitrogen monitoring. There are biochemical in vitro
experiments which have assessed if various structural fea-
tures of IgG contribute to overall stability. It is useful to
discuss such experiments insofar that the majority of
clinical studies reviewed in this manuscript illustrate a
percentage of IgG and the Fab domains retained neutral-
izing activity albeit at a reduced level and more import-
antly, that a percentage of IgG and Fab domains retain
their structural integrity, remaining intact.
Immunoglobulin structure
The base structure of Ig can be represented as a two-
dimensional “Y” (Figure 1). The IgG molecule can be di-
vided into two independent active domains: the variable
antigen binding domain or fragment and the constant
region. The antigen binding fragment, or Fab, is respon-
sible for interacting with the target antigen or epitope
via binding by the paratope or complementary deter-
mining region (CDR) (Figure 1B). IgGs are able to bind
to various antigens with high specificity due to the vari-
ability of amino acids in the CDR, since the general
folded Y-shape (tertiary structure) of Igs is conserved.
The fragment crystallizable region (Fc) is an effector to
initiate an immune response, and has no antigen binding
ability (Figure 1B).
There are two post-translational structural features of
Ig molecules which contribute to the overall stability of
the molecule: intra- and interchain covalent disulfide
bonds between cysteine residues and glycosylation
(Figure 1C). Disulfides bonds are hallmark features of
Ig stability and are also known to increase the stability of
other proteins [23-28]. Other studies link IgG glycosyla-
tion, a variable feature for the Fab domain, but a con-
served feature on the Fc domain, with stabilizing effects
[29-32]. The region most susceptible to enzymatic deg-
radation is the hinge region, which connects the Fab and
Fc domains. The hinge region is the most flexible region
of the IgG since it is the only single polypeptide region of
IgG. Studies on the susceptibility to degradation of IgG
to acidic conditions (the stomach) and digestion by en-
zymes (stomach and small intestine) are reviewed below.
Temperature and pH – in vitro
The protein melting temperature (TM) is the point at
which a protein unfolds, or denatures, and lacks the
structure necessary for activity. TM is a biochemical
measurement to probe protein structure in different sit-
uations, such as pH. Thermal stability of an IgG corre-
lates with pH: lower pH values, 2.8-3.4, corresponded to
lower average global TM values, 43.7°C-53.6°C, and
higher pH, 5.0-7.5, corresponded to higher average glo-
bal TM values, 67.5°C-68°C [33]. Even in the acidic pH
Figure 1 Simplified two-dimensional schematics of immunoglobulin G (IgG). A. Schematic showing the variable and constant regions of
the IgG molecule for the heavy (CHx) and light chains (CL); B. Schematic of the antigen binding fragments (Fab1,2) and the fragment crystallizable
region (Fc) of the IgG molecule; C. Schematic portraying intra- and interchain disulfide bonds as well as glycosylation of the Fab, Fc regions, and
paratope antigen binding regions of the IgG molecule.
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temperature, 37°C, accounting for Ig structural integrity
in the digestive tract. The addition of sugars, trehalose
[34] and sucrose [35] to experimental buffers increased
TM values for all IgGs with pH values ranging from 4.0-
8.0 suggesting that other environmental factors within
the GI tract, like dietary molecules, could increase Ig
stability. Salt content does not appear to affect IgG sta-
bility [35]. There have been isolated reports where the
CH2 domain, the most thermally stable domain of the
IgG, exhibits increased thermal stability after exposure
to pH of 2.0 [36]. This increased stability is correlated
with alternate conformations that various IgGs exhibit at
this low pH [37-39]. Some IgG purification procedures,
either from recombinant expression methods used to
produce commercially-available biologic drugs or from
naturally occurring sources, such as serum, require
acidic or basic exposure steps [40,41]. IgG molecules
purified utilizing pH shifts do not lose their capacity to
bind antigens. In fact, certain intravenous immuno-
globulin (IVIg) preparations purified with a low-pH step
have enhanced in vitro and in vivo binding to antigens
that correlates with better performance in mouse models
of sepsis [41-43]. These studies underscore that IgG re-
main stable in acidic conditions at body temperature. It
is also possible that transient exposure to acidic condi-
tions in the stomach may increase stability for survival
down the GI tract and to proteolytic enzymes.
Resistance to proteolytic digestion
Characterization of IgG structure using in vitro digestion
with proteolytic enzymes dates to the 1960s [44-47]. It is
well-established that enzymatic digestion of IgG at the
hinge region with papain produces two active domains,
Fab1,2 and Fc (Figure 1BC). Furthermore, modulating
reaction time, pH and temperature during enzymatic
digestion will result in a variety of active domainfragments [48]. The primary digestive enzymes in
humans for proteins are pepsin, in the stomach, followed
by trypsin and chymotrypsin, in the small intestine [49]
which digest IgG to Fab dimers (~100 kDa) and mono-
mer Fab fragments (~50 kDa) [15], but this enzymatic
susceptibility may vary by IgG subtype and species.
Bovine IgG1, for example, is more readily proteolyzed by
pepsin than bovine IgG2 [50]. Bovine IgG is more stable
to proteolytic digestion compared to rabbit or human
IgG [29]. Even after proteolytic digestion of IgG, Fab
dimers and monomer fragments retain binding and
antigen-neutralizing activity as long as they are not dena-
tured. Proteolytic characterization of bovine derived IgG1
in vitro demonstrates intact and reactive Fab domains
[29,50-53]. This correlates with the human in vivo study
by Roos et al. [4] demonstrating that immunologically ac-
tive bovine Fabs were recovered in ileal aspirates.
Conclusion
Twelve of the 15 human studies in infants, children and
adults that clearly demonstrate that orally-administered
Ig (particularly IgGs), from human and bovine serum as
well as from bovine colostrum and milk, survive gastric
exposure and resist proteolytic digestion in the stomach
and intestinal tract (Table 1) [4-6,9-14,16-18]. The stabil-
ity of IgG is based on the structural properties of the
molecules with contributions from intra- and interchain
disulfide bonds, post-transcriptionally added sugars, and
the three dimensional folded domains. Even when par-
tially digested by proteolytic enzymes, Fab fragments re-
tain not only binding but neutralizing activity through
the digestive tract. In addition, there is no evidence of
intact absorption of the protein, making oral IgG admin-
istration a safe, potentially effective therapy in a number
of GI conditions and diseases. These physical properties
and the ability of digested IgG fragments, Fab monomers
and Fab1,2 dimers to retain active binding activity make
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tions [54] and mitigation of damage caused by bacterial
enterotoxins, endotoxins and secreted exotoxins [55].
Studies in animals have illustrated that ingestion of
serum-derived Ig preparations, containing primarily IgG,
increase anti-inflammatory cytokines and decrease pro-
inflammatory cytokines in mucosal jejunum [56,57].
Additionally, administration of serum-derived IgG has
been shown to prevent increased intestinal permeability
induced by enterotoxin challenge [58]. Improved nutri-
ent utilization in animal models and human clinical
studies after ingestion of serum-derived immunoglobulin
preparations have also been observed [59,60]. More re-
cent studies have also shown efficacy of oral serum-
derived bovine immunoglobulin preparations, primarily
containing IgG, in such conditions as irritable bowel
syndrome with diarrhea (IBS-D) and HIV-associated en-
teropathy [59,61]. Other patients with chronic condi-
tions, such as inflammatory bowel disease (IBD) or
common variable immunodeficiency (CVID) might also
benefit from orally administered Ig preparations, con-
taining IgG, due to antigen-neutralizing activity as well
anti-inflammatory properties of these preparations. In
short, there is sufficient evidence illustrating that IgGs are
less susceptible to digestion throughout the GI tract and
therefore may provide for a distinctive nutritional require-
ment unique to patients with intestinal disorders and
diseases which other dietary proteins cannot provide.
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